1. Zhang, Luyao, Yu, Shuang, Hong, Shubin, Li, Yanbing, Xiao, Haipeng. 2023. Comprehensive analysis of BTNL9 as a prognostic biomarker correlated with immune infiltrations in thyroid cancer. In BMC medical genomics, 16, 234. doi:10.1186/s12920-023-01676-8. https://pubmed.ncbi.nlm.nih.gov/37798795/
2. Ma, Weishuang, Liang, Jiaming, Mo, Junjian, Tian, Dongbo, Chen, Zisheng. 2021. Butyrophilin-like 9 expression is associated with outcome in lung adenocarcinoma. In BMC cancer, 21, 1096. doi:10.1186/s12885-021-08790-9. https://pubmed.ncbi.nlm.nih.gov/34635082/
3. Carlson, Jenna C, Krishnan, Mohanraj, Rosenthal, Samantha L, Weeks, Daniel E, Minster, Ryan L. 2022. A stop-gain variant in BTNL9 is associated with atherogenic lipid profiles. In HGG advances, 4, 100155. doi:10.1016/j.xhgg.2022.100155. https://pubmed.ncbi.nlm.nih.gov/36340932/
4. Mo, Qingfan, Xu, Ke, Luo, Chenghao, Wang, Long, Ren, Guosheng. 2021. BTNL9 is frequently downregulated and inhibits proliferation and metastasis via the P53/CDC25C and P53/GADD45 pathways in breast cancer. In Biochemical and biophysical research communications, 553, 17-24. doi:10.1016/j.bbrc.2021.03.022. https://pubmed.ncbi.nlm.nih.gov/33756341/
5. Dunk, C E, Roggensack, A M, Cox, B, Kingdom, J C P, Adamson, S L. 2012. A distinct microvascular endothelial gene expression profile in severe IUGR placentas. In Placenta, 33, 285-93. doi:10.1016/j.placenta.2011.12.020. https://pubmed.ncbi.nlm.nih.gov/22264586/
智鼠故事 
